Plain-English translation of NCT03855137 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial studied atogepant, a new medication designed to prevent chronic migraines. Researchers tested whether this treatment could reduce how often people with chronic migraines experienced headaches. The study included nearly 800 participants and lasted 12 weeks to see if the medication was safe and effective.
Chronic migraines can be debilitating and significantly affect quality of life. This trial was designed to test whether this new medication could offer people with frequent migraines a better preventive option with fewer side effects than some existing treatments.
Participants received either a placebo (inactive pill) or the medication at one of two different doses, taking tablets by mouth twice daily for 12 weeks. All participants were monitored in a double-blind study, meaning neither they nor the researchers knew who received the actual medication versus placebo. Throughout the trial, participants tracked their headaches daily using an electronic diary and attended visits to assess whether the treatment was working and how well they tolerated it.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States